



Notification 6602

Category

HCPCS - Drugs & Biologicals

Topic

Louisiana Medicaid – golimumab, 2 mg

What is changing?

We limit reimbursement of charges for golimumab, 2 mg, to no more than 4 administrations every 26 weeks (if billed with any of the following indications):

- Arthropathic psoriasis
- Felty's Syndrome, shoulder
- Rheumatoid lung disease with rheumatoid arthritis
- Rheumatoid vasculitis with rheumatoid arthritis
- Rheumatoid heart disease with rheumatoid arthritis
- Rheumatoid myopathy with rheumatoid arthritis
- Rheumatoid polyneuropathy with rheumatoid arthritis
- Rheumatoid arthritis with involvement of other organs and systems
- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
- Other rheumatoid arthritis with rheumatoid factor
- Rheumatoid arthritis without rheumatoid factor
- Adult-onset Still's disease
- Rheumatoid bursitis
- Rheumatoid nodule
- Inflammatory polyarthropathy
- Other specified rheumatoid arthritis
- Enteropathic arthropathies
- Palindromic rheumatism
- Ankylosing spondylitis
- Arthropathic psoriasis
- Juvenile arthritis
- Juvenile ankylosing spondylitis
- Juvenile rheumatoid arthritis with systemic onset

Language

English

Impacted Products
Medicaid – Louisiana

Why is Humana making this change?

The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.